MRX2843, A NOVEL DUAL MERTK & FLT3 INHIBITOR WITH ACTIVITY AGAINST RESISTANCE-CONFERRING FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA

Minson Katherine; Smith Catherine; Lee-Sherick Alisa; Libbrecht Clara; DeRyckere Deborah; Lasater Elisabeth; Hill Amanda; Wang Xiaodong; Frye Stephen; Earp H. Shelton III; Shah Neil; Graham Douglas

首页> 外文期刊>Pediatric blood & cancer >MRX2843, A NOVEL DUAL MERTK & FLT3 INHIBITOR WITH ACTIVITY AGAINST RESISTANCE-CONFERRING FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA

【24h】

MRX2843, A NOVEL DUAL MERTK & FLT3 INHIBITOR WITH ACTIVITY AGAINST RESISTANCE-CONFERRING FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA

机译：MRX2843，一种新型双重MERTK和FLT3抑制剂，具有抗急性髓样白血病的赋予抗药性的FLT3突变的活性。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric blood & cancer》 |2015年第2期|共1页
作者
Minson Katherine; Smith Catherine; Lee-Sherick Alisa; Libbrecht Clara; DeRyckere Deborah; Lasater Elisabeth; Hill Amanda; Wang Xiaodong; Frye Stephen; Earp H. Shelton III; Shah Neil; Graham Douglas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词

相似文献

外文文献
中文文献
专利

1. 急性髓系白血病患者外周血细胞中FLT3基因表达与FLT3/ITD突变的关系及其意义 [J] . 徐兵, 史鹏程, 宋小燕, 癌症（英文版） . 2009,第006期
2. MRX2843, A NOVEL DUAL MERTK & FLT3 INHIBITOR WITH ACTIVITY AGAINST RESISTANCE-CONFERRING FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA [J] . Minson Katherine, Smith Catherine, Lee-Sherick Alisa, Pediatric blood & cancer . 2015,第Suppla2期

机译：MRX2843，一种新型双重MERTK和FLT3抑制剂，具有抗急性髓样白血病的赋予抗药性的FLT3突变的活性。
3. The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations [J] . Zhang Weiguo, Borthakur Gautam, Gao Chen, Cancer research: The official organ of the American Association for Cancer Research, Inc . 2016,第6期

机译：MEK / FLT3双重抑制剂E6201对具有耐药性的FLT3突变的急性髓样白血病细胞具有细胞毒活性。
4. Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines [J] . Dayal Neetu, Opoku-Temeng Clement, Hernandez Delmis E., Future medicinal chemistry . 2018,第7期

机译：双重FLT3 / TOPK抑制剂对FLT3-ITD二级突变的活性效果抑制急性髓性白血病细胞系
5. Tandem mass spectrometry characterizes the related substances of second generation FLT3 inhibitor Quizartinib, anti cancer compound for myeloid leukemia [C] . Saravanan Subramaniyan, Arvind Thyagarajan, Rampriya Uthayakumar, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：串联质谱表征第二代FLT3抑制剂Quizartinib的相关物质，用于髓性白血病的抗癌化合物
6. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
7. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia [O] . Katherine A. Minson, Catherine C. Smith, Deborah DeRyckere, 2016

机译：MERTK / FLT3抑制剂MRX-2843克服了急性髓细胞白血病中赋予耐药性的FLT3突变
8. The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations [O] . Weiguo Zhang, Gautam Borthakur, Chen Gao, 2016

机译：双重MEK / FLT3抑制剂E6201对患有抵抗抵抗抵抗力的FLT3突变的急性髓性白血病细胞施加细胞毒性活性

MRX2843, A NOVEL DUAL MERTK & FLT3 INHIBITOR WITH ACTIVITY AGAINST RESISTANCE-CONFERRING FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA

著录项

相似文献

相关主题

期刊订阅